Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK615 is an extract from the Japanese apricot (*Prunus mume*), standardized to contain several cyclic triterpenoids. It has demonstrated anti-neoplastic effects in vitro and in vivo, primarily against various cancer cell lines and tumors. Its mechanisms involve inhibition of growth by induction of apoptosis, autophagy, suppression of Aurora A kinase, downregulation of PD-L1 and NF-κB signaling, and activation of T cell–mediated anti-tumor immunity. Both preclinical and small early clinical studies suggest activity in colon cancer, hepatocellular carcinoma (HCC), breast cancer, and pancreatic cancer. MK615 is not a single compound but a defined mixture from a natural source.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MK615.